923 related articles for article (PubMed ID: 21371602)
1. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
Maurer T
Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
[TBL] [Abstract][Full Text] [Related]
2. Effective progression of nuclear magnetic resonance-detected fragment hits.
Eaton HL; Wyss DF
Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
[TBL] [Abstract][Full Text] [Related]
3. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
4. Practical aspects of NMR-based fragment screening.
Lepre CA
Methods Enzymol; 2011; 493():219-39. PubMed ID: 21371593
[TBL] [Abstract][Full Text] [Related]
5. Fragment-based ligand discovery.
Fischer M; Hubbard RE
Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
[TBL] [Abstract][Full Text] [Related]
6. Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine.
Vulpetti A; Hommel U; Landrum G; Lewis R; Dalvit C
J Am Chem Soc; 2009 Sep; 131(36):12949-59. PubMed ID: 19702332
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in fragment-based lead discovery.
Schulz MN; Hubbard RE
Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
[TBL] [Abstract][Full Text] [Related]
8. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.
Woodhead AJ; Angove H; Carr MG; Chessari G; Congreve M; Coyle JE; Cosme J; Graham B; Day PJ; Downham R; Fazal L; Feltell R; Figueroa E; Frederickson M; Lewis J; McMenamin R; Murray CW; O'Brien MA; Parra L; Patel S; Phillips T; Rees DC; Rich S; Smith DM; Trewartha G; Vinkovic M; Williams B; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5956-69. PubMed ID: 20662534
[TBL] [Abstract][Full Text] [Related]
9. Fragment based drug discovery: practical implementation based on ¹⁹F NMR spectroscopy.
Jordan JB; Poppe L; Xia X; Cheng AC; Sun Y; Michelsen K; Eastwood H; Schnier PD; Nixey T; Zhong W
J Med Chem; 2012 Jan; 55(2):678-87. PubMed ID: 22165820
[TBL] [Abstract][Full Text] [Related]
10. Two 'Golden Ratio' indices in fragment-based drug discovery.
Orita M; Ohno K; Niimi T
Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
[TBL] [Abstract][Full Text] [Related]
11. Experiences in fragment-based lead discovery.
Hubbard RE; Murray JB
Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
[TBL] [Abstract][Full Text] [Related]
12. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
13. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
[TBL] [Abstract][Full Text] [Related]
14. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
[TBL] [Abstract][Full Text] [Related]
15. Informatics and modeling challenges in fragment-based drug discovery.
Hubbard RE; Chen I; Davis B
Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
[TBL] [Abstract][Full Text] [Related]
16. Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
Barelier S; Krimm I
Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360
[TBL] [Abstract][Full Text] [Related]
17. NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery.
Moore JM
Biopolymers; 1999; 51(3):221-43. PubMed ID: 10516573
[TBL] [Abstract][Full Text] [Related]
18. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
Ma R; Wang P; Wu J; Ruan K
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
[TBL] [Abstract][Full Text] [Related]
19. Establish an automated flow injection ESI-MS method for the screening of fragment based libraries: Application to Hsp90.
Riccardi Sirtori F; Caronni D; Colombo M; Dalvit C; Paolucci M; Regazzoni L; Visco C; Fogliatto G
Eur J Pharm Sci; 2015 Aug; 76():83-94. PubMed ID: 25952103
[TBL] [Abstract][Full Text] [Related]
20. NMR fragment screening: Advantages and applications.
Schade M
IDrugs; 2006 Feb; 9(2):110-3. PubMed ID: 16523400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
